South San Francisco, United States
Maze Therapeutics is a biotechnology startup that envisions a world where genetic insights inspire new medicines. Founded in 2018 and headquartered in the United States, they are focused on translating novel genetic insights into lifesaving medicines. Their approach integrates human genetics and functional genomics, aiming to decode the mysteries of genetic modifiers in severe diseases. They aspire to develop medicines that mimic protective mutations.
The company recently secured a $190.00M in a Venture Round investment on 10 January 2022. The impressive list of investors in this round includes Casdin Capital, General Catalyst, City Hill Ventures, Driehaus Capital Management, Foresite Capital, Matrix Capital Management, Moore Strategic Ventures, NS Investment, Terra Magnum Capital Partners, and Woodline Partners.
Maze Therapeutics has assembled a world-class team, comprising creative scientific pioneers in genetics, experienced company builders, and biotech industry leaders, to realize their vision of developing innovative medicines that address severe diseases through a genetic lens.
